Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
JACC Cardiovasc Imaging. 2018 Apr;11(4):628-643. doi: 10.1016/j.jcmg.2018.01.009.
Mitral valve regurgitation (MR) is the most common valvular heart disease. Primary MR is a disease of the mitral valve apparatus, whereas secondary MR is a disease of the left ventricle. Diagnosing and managing MR is often challenging and requires a structured approach, integrating findings on history, physical examination, and imaging. Decisions regarding treatment depend on knowledge of the etiology, natural history, and outcome of interventions for these patients with mitral valve disease. The optimal timing of intervention requires a comprehensive 2-dimensional and Doppler echocardiogram in each patient to determine the cause of the mitral valve disease, the severity of the regurgitation, and the effect of the volume overload on the left ventricle, as well as determining if a durable valve repair can be performed. Advances in both surgical and catheter-based therapies have resulted in recommendations for lower thresholds for operation and extension of interventional treatments to the older, sicker population of patients with MR. The current review discusses the pathophysiological rationale for current diagnostic and management strategies in MR.
二尖瓣反流(MR)是最常见的瓣膜性心脏病。原发性 MR 是二尖瓣装置的疾病,而继发性 MR 是左心室的疾病。诊断和治疗 MR 通常具有挑战性,需要采用一种结构化的方法,综合病史、体格检查和影像学检查的结果。治疗决策取决于对这些二尖瓣疾病患者的病因、自然病程和干预结果的了解。干预的最佳时机需要对每位患者进行全面的二维和多普勒超声心动图检查,以确定二尖瓣疾病的病因、反流的严重程度以及左心室容量超负荷的影响,并确定是否可以进行持久的瓣膜修复。手术和导管治疗方面的进展使得手术的门槛降低,并将介入治疗扩展到患有 MR 的年龄更大、病情更重的患者群体。目前的综述讨论了当前 MR 诊断和治疗策略的病理生理基础。